Nephrotoxicity in patients on long-term platinum (II) chemotherapy constitutes a limit both in dosage and duration of chemotherapy; successful use of adjuvant platinum chemotherapy requires a solution to this problem. The principal investigator has recently demonstrated the success of a dithiocarbamate rescue procedure to inhibit nephrotoxicity in an animal model. The research proposed herein is designed: (1) to provide information about the interaction of dithiocarbamate with membrane-bound platinum and platinum DNA complexes and hence increase our knowledge of the mechanism of platinum toxicity; (2) to confirm that cis-platinum, when given in combination with dithiocarbamate, is still effective as an anti-tumor agent; (3) to demonstrate that oral disulfiram is an effective rescue agent for platinum toxicity. The interaction of dithiocarbamate and preformed complexes of platinum with renal tubular membranes and with DNA will be evaluated spectrophotometrically to determine whether dithiocarbamate can remove platinum from these complexes. Administration of cis-platinum and dithiocarbamate will be carried out in tumor-bearing animals and the effect of the drug combination on tumor size compared with that of platinum alone. The pharmacokinetics of oral disulfiram in the rabbit will be explored as a model for this drug as a rescue agent in a clinical setting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA034620-04
Application #
3172372
Study Section
Toxicology Study Section (TOX)
Project Start
1982-09-01
Project End
1986-02-28
Budget Start
1985-03-01
Budget End
1986-02-28
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Medicine
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Kennedy, S M; Borch, R F (1999) IL-1beta mediates diethyldithiocarbamate-induced granulocyte colony-stimulating factor production and hematopoiesis. Exp Hematol 27:210-6
Patil, R R; Borch, R F (1995) Granulocyte-macrophage colony-stimulating factor expression by human fibroblasts is both upregulated and subsequently downregulated by interleukin-1. Blood 85:80-6
East, C J; Abboud, C N; Borch, R F (1992) Diethyldithiocarbamate induction of cytokine release in human long-term bone marrow cultures. Blood 80:1172-7
Montine, T J; Borch, R F (1990) Role of endogenous sulfur-containing nucleophiles in an in vitro model of cis-diamminedichloroplatinum(II)-induced nephrotoxicity. Biochem Pharmacol 39:1751-7
Schmalbach, T K; Borch, R F (1989) Diethyldithiocarbamate modulation of murine bone marrow toxicity induced by cis-diammine(cyclobutanedicarboxylato)platinum (II). Cancer Res 49:6629-33
Schmalbach, T K; Borch, R F (1989) Myeloprotective effect of diethyldithiocarbamate treatment following 1,3-bis(2-chloroethyl)-1-nitrosourea, adriamycin, or mitomycin C in mice. Cancer Res 49:2574-7
DeGregorio, M W; Gandara, D R; Holleran, W M et al. (1989) High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations. Cancer Chemother Pharmacol 23:276-8
Gringeri, A; Keng, P C; Borch, R F (1988) Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II). Cancer Res 48:5708-12
Montine, T J; Borch, R F (1988) Quiescent LLC-PK1 cells as a model for cis-diamminedichloroplatinum(II) nephrotoxicity and modulation by thiol rescue agents. Cancer Res 48:6017-24
Dedon, P C; Borch, R F (1987) Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles. Biochem Pharmacol 36:1955-64

Showing the most recent 10 out of 12 publications